The United States: Global Leadership in the Development of Rare Disease Treatments
In an era of healthcare reform and heightened scrutiny of pharmaceutical innovation, America’s leadership in rare disease drug development stands out as a remarkable achievement. This progress has been shaped by the dedication of the rare disease patient community—families and advocacy organizations like the National Organization for Rare Disorders (NORD), the Friedreich’s Ataxia Research Alliance […]
Rare Disease Research in Latin America: A Landscape of Promise and Potential
By: Juan Francisco Cabello, MD and Marshall Summar, MD Latin America offers a dynamic and promising environment for rare disease research, characterized by growing momentum within the medical community to meet the unique needs of those affected. Collaboration across countries and sectors is unlocking new opportunities for innovation and progress. The region’s rich diversity—encompassing social, […]
Parent and Patient-Driven Discovery and Research in Rare Diseases
By Simon Frost and Marshall Summar Rare diseases, defined as conditions affecting fewer than 200,000 individuals in the United States, present significant challenges to the healthcare system. With limited financial incentives for pharmaceutical companies and sparse knowledge about these conditions, families and patients have by necessity often taken the lead in driving discovery and advancing […]
The Ethics of Rare Disease Clinical Trials: Balancing Innovation, Urgency, and Responsibility
Introduction Rare disease clinical trials are a vital intersection of scientific discovery and ethical responsibility. These trials provide hope for patients with life-altering conditions but also present unique ethical challenges. With small patient populations, urgent unmet needs, and, experimental treatments researchers and sponsors must carefully balance the needs of patients with rigorous standards of safety, […]
An Opportunity for FDA and Rare Disease
Rare disease research and drug development are at a transformative crossroads, with the FDA uniquely positioned to lead the charge in accelerating innovation. By embracing legislative support, fostering collaboration with the NIH, and adopting flexible regulatory models, the FDA can redefine the future of clinical trials for rare diseases. This shift will not only address […]
Now is the Time to Invest in Rare Disease
Why Now is the Time to Invest in Rare Disease Therapies As a new administration takes charge and the spotlight intensifies on the challenges posed by big pharma, the pharmaceutical industry faces both scrutiny and opportunity. Amid this evolving landscape, a compelling case emerges for investing in the development of rare disease therapies. These treatments, […]